- Home
- RVMD vs BBIO Comparison
RVMD vs BBIO Comparison
Compare RVMD & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | BBIO |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 14.7B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RVMD | BBIO |
|---|---|---|
| Price | $121.05 | $77.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $81.19 | $78.71 |
| AVG Volume (30 Days) | ★ 4.8M | 2.2M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $353,780,000.00 |
| Revenue This Year | N/A | $127.64 |
| Revenue Next Year | $714.50 | $78.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $29.17 | $28.10 |
| 52 Week High | $121.62 | $79.88 |
Technical Indicators
Market Signals| Indicator | RVMD | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 89.60 | 59.63 |
| Support Level | $76.28 | $70.95 |
| Resistance Level | $121.62 | $79.88 |
| Average True Range (ATR) | 5.89 | 3.06 |
| MACD | 4.05 | -0.07 |
| Stochastic Oscillator | 97.30 | 78.28 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.